American bio company Modena says it has entered a phase 2 clinical trial to develop a Corona 19 vaccine on the 29th.

Modena explained in a press release that the first participant in the Phase 2 trial was given a vaccine candidate (mRNA-1273) and that it would eventually be administered to 600 people.

Participants were divided into two groups of 18-55 years old and 55 years old or older, according to their age.

Earlier, Modena announced that the first phase of clinical trials announced on the 18th revealed that corona19 antibodies had been formed in all 45 participants, which signaled the development of vaccines throughout the year.

Modena's share price soared nearly 20% on the day of the first phase announcement, but declined 10% the next day as a result of the objection that participants' age information was insufficient.

Modena plans to begin phase 3 clinical trials in July.

Currently, there are about 10 vaccine candidates in human trials worldwide, including Modena, and experts believe that it will take 12 to 18 months before a safe and effective vaccine is developed, Reuters said.

(Photo = Getty Image Korea)